CAS 867160-71-2

Linsitinib

Description:

Linsitinib, with the CAS number 867160-71-2, is a small molecule inhibitor primarily targeting the insulin-like growth factor 1 receptor (IGF-1R) and the insulin receptor (IR). It is classified as a tyrosine kinase inhibitor and is notable for its potential therapeutic applications in oncology, particularly in the treatment of various cancers, including those resistant to conventional therapies. Linsitinib exhibits a unique mechanism of action by disrupting the signaling pathways associated with cell proliferation and survival, which are often upregulated in cancerous cells. The compound is typically administered orally and has been evaluated in clinical trials for its efficacy and safety profile. In terms of its chemical structure, Linsitinib contains multiple functional groups that contribute to its biological activity and solubility characteristics. As with many pharmaceutical agents, its pharmacokinetics, including absorption, distribution, metabolism, and excretion, are critical for determining its therapeutic potential and dosing regimens. Overall, Linsitinib represents a significant advancement in targeted cancer therapies.

Formula: C₂₆H₂₃N₅O

InChI: InChI=1/C26H23N5O/c1-26(32)14-19(15-26)25-30-22(23-24(27)28-11-12-31(23)25)18-8-7-17-9-10-20(29-21(17)13-18)16-5-3-2-4-6-16/h2-13,19,32H,14-15H2,1H3,(H2,27,28)/t19-,26+

InChI key: InChIKey=PKCDDUHJAFVJJB-VLZXCDOPNA-N

SMILES: NC=1C=2N(C(=NC2C3=CC4=C(C=C3)C=CC(=N4)C5=CC=CC=C5)[C@H]6C[C@@](C)(O)C6)C=CN1

Synonyms:

• Cyclobutanol, 3-[8-amino-1-(2-phenyl-7-quinolinyl)imidazo[1,5-a]pyrazin-3-yl]-1-methyl-, cis-
• Linsitinib
• Osi 906Aa
• Osi-906
• cis-3-[8-Amino-1-(2-phenyl-7-quinolinyl)imidazo[1,5-a]pyrazin-3-yl]-1-methylcyclobutanol
• cis-3-[8-Amino-1-(2-phenyl-7-quinolinyl)imidazo[1,5-a]pyrazin-3-yl]-1-methylcyclobutanol Linsitinib(OSI906)
• 3-(8-Amino-1-(2-phenylquinolin-7-yl)-2,3-dihydro-imidazo[1,5-a]pyrazin-3-yl)-1-methylcyclobuta
• Linsitinib(OSI906)
• Linsitinib, Free Base
• (1S,3r)-3-((S)-8-aMino-1-(2-phenylquinolin-7-yl)-2,3-dihydroiMidazo[1,5-a]pyrazin-3-yl)-1-Methylcyclobutanol
• (1s,3r)-3-[4-aMino-3-(2-phenylquinolin-7-yl)iMidazo[1,5-a]pyrazin-1-yl]-1-Methylcyclobutan-1-ol
• (1s,3s)-3-(8-amino-1-(2-phenylquinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl)-1-methylcyclobutanol

OSI-906 (Linsitinib)

CAS: 867160-71-2

Formula: C₂₆H₂₃N₅O

Purity: 98%

Color and Shape: Solid

Molecular weight: 421.4937

Ref: IN-DA00GU3Y

Cis-3-(8-Amino-1-(2-Phenylquinolin-7-Yl)Imidazo[1,5-A]Pyrazin-3-Yl)-1-Methylcyclobutan-1-Ol

CAS: 867160-71-2

Cis-3-(8-Amino-1-(2-Phenylquinolin-7-Yl)Imidazo[1,5-A]Pyrazin-3-Yl)-1-Methylcyclobutan-1-Ol

Purity: 98%

Molecular weight: 421.49g/mol

Ref: 54-OR1023245

Linsitinib

CAS: 867160-71-2

Linsitinib

Purity: ≥95%

Molecular weight: 421.49g/mol

Ref: 54-BUP13134

Linsitinib

CAS: 867160-71-2

OSI-906 (Linsitinib) is an oral inhibitor of IGF-1R with anti-cancer properties, potentially halting tumor growth and inducing cell death.

Formula: C₂₆H₂₃N₅O

Purity: 99.71% - ≥95%

Color and Shape: Solid

Molecular weight: 421.49

Ref: TM-T6017

Linsitinib

CAS: 867160-71-2

Color and Shape: Solid

Molecular weight: 421.503997802734

Ref: 10-F884006

Linsitinib

CAS: 867160-71-2

Dual IGF-1R and InsR kinase inhibitor; antineoplastic

Formula: C₂₆H₂₃N₅O

Purity: Min. 95%

Color and Shape: Off-White To Yellow Solid

Molecular weight: 421.49 g/mol

Ref: 3D-FO65116

Linsitinib

Controlled Product

CAS: 867160-71-2

Applications Linsitinib is a small-molecule dual insulin-like growth factor-1 receptor (IGF-IR) and insulin receptor (IR) kinase inhibitor. IGF-I receptor (IGF-IR) has been implicated in the promotion of tumorigenesis, metastasis and resistance to cancer therapies and thus Linsitinib may be a useful anticancer agent. Potent IGF-1R inhibitor.
References Mulvihill, M.M.J. et al.: Fut. Med. Chem., 1, 1153 (2009); Flanigan, S.A. et al.: Clin. Cancer Res., 16, 5436 (2010); McKinley, E.T. et al.: Clin. Cancer Res., 17, 3332 (2011);

Formula: C₂₆H₂₃N₅O

Color and Shape: Neat

Molecular weight: 421.49

Ref: TR-L469020